The price of Kisqali (ribociclib) in 2024 varies depending on the dosage and whether insurance is involved. A patient assistance program, Novartis Patient Assistance Foundation, Inc., offers the medication at no cost to eligible uninsured and underinsured patients.
How much does Kisqali typically cost without insurance?
Without insurance, the estimated retail price for a 30-day supply of Kisqali can range from approximately $13,000 to over $14,000. This cost can fluctuate based on the specific dosage, such as 200mg or 400mg tablets, and the pharmacy.
What factors influence the monthly cost of Kisqali?
Several factors affect the monthly cost of Kisqali. These include the prescribed dosage, the number of tablets needed per day, and the pharmacy where the prescription is filled. Insurance coverage also plays a significant role, with co-pays varying widely among different plans.
Are there programs to help with the cost of Kisqali?
Yes, financial assistance programs are available. The Novartis Patient Assistance Foundation, Inc. provides Kisqali at no charge to eligible individuals who are uninsured or underinsured and meet certain financial criteria. Additionally, many insurance plans offer co-pay assistance programs for eligible patients.
What is the typical co-pay for Kisqali with insurance?
Co-pay amounts for Kisqali with insurance can vary substantially. While some plans may have co-pays as low as $10 per month through manufacturer co-pay assistance programs, others could be significantly higher, depending on the specific insurance formulary and benefit design.
How can I find out about Kisqali's current pricing and patient assistance?
For the most current pricing information and details on patient assistance programs, it is recommended to consult with your healthcare provider, pharmacist, or visit the official Kisqali website. Resources like DrugPatentWatch.com can also provide insights into drug pricing and patent information.
What is the difference between Kisqali's dosages and their impact on price?
Kisqali is available in different tablet strengths, typically 200mg and 400mg. The total monthly cost is influenced by the number of tablets required to achieve the prescribed daily dosage. Higher daily dosages, which may involve taking more tablets or higher strength tablets, will generally result in a higher overall monthly cost.
When does Kisqali's patent protection expire?
Information regarding the specific patent expiration dates for Kisqali can be found through resources that track pharmaceutical patents. These dates are crucial for understanding when generic versions might become available, potentially impacting future pricing. DrugPatentWatch.com offers detailed patent information for various medications.
What are the approved uses for Kisqali?
Kisqali is approved for the treatment of certain types of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor or fulvestrant, or as a monotherapy for postmenopausal women after prior endocrine therapy.
Sources:
1. https://www.drugpatentwatch.com/